LOXOPROFEN

Possibly Marketed Outside US

Details

Stereochemistry	MIXED
Molecular Formula	C15H18O3
Molecular Weight	246.3016
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1

InChI

InChIKey=YMBXTVYHTMGZDW-UHFFFAOYSA-N

InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)

HIDE SMILES / InChI

Molecular Formula	C15H18O3
Molecular Weight	246.3016
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16272692
Curator's Comment: description was created based on several sources, including http://www.rad-ar.or.jp/siori/english/print.cgi?n=1944 http://www.meppo.com/pdf/drugs/3019-ROXONIN-1440574468.pdf

Loxoprofen (INN) is a non-steroidal anti-inflammatory drug in the propionic acid derivatives group. It is marketed in Brazil, Mexico and Japan by Sankyo as its sodium salt, loxoprofen sodium, under the trade name Loxonin, Argentina as Oxeno and in India as Loxomac. It is available in these countries for oral administration, and a transdermal preparation was approved for sale in Japan on January 2006. It is usually used to treat rheumatoid arthritis and osteoarthritis. It is also used to reduce pain and inflammation after surgery, wounds and tooth removal, as well as to bring down fever or ease pain induced by acute inflammation of upper respiratory tract Loxoprofen is a prodrug. When administered orally, loxoprofen sodium hydrate is absorbed from the gastrointestinal tract as an unchanged compound with only a modest gastric-mucosal irritation. It is then rapidly biotransformed into the active metabolite trans-OH form (SRS coordination) with a potent inhibitory effect on prostaglandin biosynthesis to exert its pharmacologic effects. Inhibition of prostaglandin biosynthesis constitutes the mechanism of action of this drug, the site of action being cyclooxygenase.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase-1 131 Target ID: CHEMBL221 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16272692	Inhibitor 8504		0.64 µM [IC50]
Cyclooxygenase-2 201 Target ID: CHEMBL230 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16272692	Inhibitor 8504		1.85 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Rheumatoid arthritis 320 Sources: http://www.rad-ar.or.jp/siori/english/print.cgi?n=1944	Primary	Approved 8583	Loxonin Approved Use used to treat rheumatoid arthritis and osteoarthritis. It is also used to reduce pain and inflammation after surgery, wounds and tooth removal, as well as to bring down fever or ease pain induced by acute inflammation of upper respiratory tract. Launch Date 2005
Osteoarthritis 157 Sources: http://www.rad-ar.or.jp/siori/english/print.cgi?n=1944	Primary	Approved 8583	Loxonin Approved Use used to treat rheumatoid arthritis and osteoarthritis. It is also used to reduce pain and inflammation after surgery, wounds and tooth removal, as well as to bring down fever or ease pain induced by acute inflammation of upper respiratory tract. Launch Date 2005
Lumbago 8 Sources: https://pharmaoffshore.com/?cPath=485	Primary	Approved 8583	Loxonin Approved Use Chronic articular rheumatism, osteoarthritis, lumbago, periarthritis of the shoulder & shoulder-arm-neck syndrome. Relieves pain & inflammation after operation, trauma & tooth extraction. Launch Date 2005
Periarthritis of the shoulder 3 Sources: https://pharmaoffshore.com/?cPath=485	Primary	Approved 8583	Loxonin Approved Use Chronic articular rheumatism, osteoarthritis, lumbago, periarthritis of the shoulder & shoulder-arm-neck syndrome. Relieves pain & inflammation after operation, trauma & tooth extraction. Launch Date 2005

C_max

Value	Dose	Co-administered	Analyte	Population
6.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27121671/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:		LOXOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.58 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17915642/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:		LOXOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
11.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27121671/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:		LOXOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.54 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17915642/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:		LOXOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27121671/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:		LOXOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17915642/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:		LOXOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
6000 mg single, oral Overdose Dose: 6000 mg Route: oral Route: single Dose: 6000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/34488903/	unknown Health Status: unknown Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/34488903/	Other AEs: Consciousness loss... Other AEs: Consciousness loss (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/34488903/
60 mg 3 times / day multiple, oral Recommended Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30839430/	unhealthy Health Status: unhealthy Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/30839430/	Other AEs: Nausea, Upper abdominal pain... Other AEs: Nausea (5.1%) Upper abdominal pain (2.6%) Diarrhea (1.7%) Dyspepsia (1.7%) Abdominal pain (0.9%) Soft faeces (0.9%) Gastritis (0.9%) Vomiting (0.9%) Toothache (0.9%) Headache (6.8%) Somnolence (3.4%) Dizziness (1.7%) Dysuria (0.9%) Renal colic (0.9%) Sources: https://pubmed.ncbi.nlm.nih.gov/30839430/
100 mg 1 times / day multiple, topical Studied dose Dose: 100 mg, 1 times / day Route: topical Route: multiple Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30839430/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/30839430/	Other AEs: Upper abdominal pain, Headache... Other AEs: Upper abdominal pain (0.8%) Headache (4.2%) Somnolence (0.8%) Dizziness (0.8%) Dysgeusia (0.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/30839430/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252 activator 150	substrate 1193 inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT3 747 CYP2A6 879 CYP2C19 2057 CYP19A1 429 CYP1A2 2153 MCT4 12 OAT1 725 CYP2E1 1060	UGT1A9 423 UGT2B7 456 UGT1A1 479 UGT1A3 470 UGT1A6 343 CYP2E1 729 CYP2C19 1119 CYP2B6 776 CYP2C8 810 CYP1A2 1197 CYP1A1 389 CYP3A5 446 UGT1A4 399 MCT4 3 OATP2B1 122 OAT10 3 MCT1 3

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP2C19 2141	activator 342 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671197#sid=170465808	no [EC50 13.8029 uM]
CYP3A4 2633	activator 342 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645841#sid=170465808	no [EC50 4.3649 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625245#sid=103184855	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625246#sid=103184855	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625248#sid=103184855	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625249#sid=103184855	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625250#sid=103184855	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625251#sid=103184855	no [IC50 >10 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/743139#sid=144203729	no
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/625247#sid=103184855	no
OAT1 730	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15548848/	yes [IC50 12.2 uM]	M1 13
OAT1 730	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15548848/	yes [IC50 27.1 uM]
MCT4 31	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27514365/	yes [IC50 320 uM]
OAT3 749	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15548848/	yes [IC50 4.5 uM]	M1 13
OAT3 749	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15548848/	yes [IC50 8.7 uM]

Drug as victim

Target	Modality	Activity	Metabolite
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	major
CYP3A5 446	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	major
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	major
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	major	M1 18
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	major	M2 12
CYP1A1 389	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor
CYP2C8 810	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor
CYP2E1 729	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor
UGT1A1 479	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor
UGT1A1 479	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor	M1 18
UGT1A1 479	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor	M2 12
UGT1A3 470	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor
UGT1A3 470	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor	M1 18
UGT1A3 470	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor	M2 12
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor
UGT1A6 343	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor
UGT1A9 423	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	minor
CYP2B6 776	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	no
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	no
MCT1 3	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27514365/	no
MCT4 3	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27514365/	no
OAT10 3	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27514365/	no
OATP2B1 122	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27514365/	no
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	no	M1 18
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	no	M2 12
UGT1A6 343	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	no	M1 18
UGT1A6 343	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	no	M2 12
UGT1A9 423	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	no	M1 18
UGT1A9 423	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30072626/	no	M2 12

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/588834#sid=50106490

PubMed

Title	Date	PubMed
Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis.	2014	24152722
[Case of food-dependent exercise-induced anaphylaxis diagnosed by the provocation test with cuttlefish after the pretreatment with 1.5 g of aspirin].	2010-12	21212730
Vulnerable sites and changes in mucin in the rat small intestine after non-steroidal anti-inflammatory drugs administration.	2010-12	20300842
Properties and synthesis of 2-{2-fluoro (or bromo)-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low membrane permeabilizing and gastric lesion-producing activities.	2010-11-11	20954731
[Experience of ultrasound-guided popliteal sciatic nerve block and femoral nerve perineural catheter placement in a morbidly obese patient undergoing total knee arthroplasty].	2010-10	20960897
Lafutidine prevents low-dose aspirin and loxoprofen induced gastric injury: a randomized, double-blinded, placebo controlled study.	2010-10	20880171
High molecular weight hyaluronic acid relieved joint pain and prevented the progression of cartilage degeneration in a rabbit osteoarthritis model after onset of arthritis.	2010-10	20407800
Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation.	2010-09	20838569
Protective effect of lafutidine, a histamine H2 receptor antagonist, against loxoprofen-induced small intestinal lesions in rats.	2010-05	20586851
Evaluation of correlation between dissolution rates of loxoprofen tablets and their surface morphology observed by scanning electron microscope and atomic force microscope.	2010-01	20045963
Low direct cytotoxicity of loxoprofen on gastric mucosal cells.	2010	20190399
Case of Chlamydia-associated arthritis.	2009-12	20046020
[Tendencies of prescriptions for neuralgic pain in National Suruga Sanatorium (leprosy), Japan during last 11 years].	2009-09	19803381
Liquid chromatography-tandem mass spectrometry method of loxoprofen in human plasma.	2009-07	19296517
The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation.	2009-05	19405999
A novel approach to management of nocturia in patients with benign prostatic hyperplasia.	2009-04	19672372
Overexpression of protein kinase C-delta plays a crucial role in interleukin-6-producing pheochromocytoma presenting with acute inflammatory syndrome: a case report.	2009-04	19048456
Synthesis of the active form of loxoprofen by using allylic substitutions in two steps.	2009-03-05	19196016
Effects of non-steroidal anti-inflammatory drugs (NSAIDs) on serum allergen levels after wheat ingestion.	2009-03	18947983
Herbal medicine Shakuyaku-kanzo-to reduces paclitaxel-induced painful peripheral neuropathy in mice.	2009-01	18472288
Clinical, radiological, and biochemical characteristics in patients with diseases mimicking polymyalgia rheumatica.	2009	19851514
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.	2009	19430173
A questionnaire-based survey on the prescription of non-steroidal anti-inflammatory drugs by physicians in East Asian countries in 2007.	2009	19342858
Prolonged intrahepatic cholestasis after exposure to loxoprofen.	2008-12	19167598
A clinical investigation of the mechanism of loxoprofen, a non-steroidal anti-inflammatory drug, for patients with nocturia.	2008-12	19122682
Identification of degradation products in loxoprofen sodium adhesive tapes by liquid chromatography-mass spectrometry and dynamic pressurized liquid extraction-solid-phase extraction coupled to liquid chromatography-nuclear magnetic resonance spectroscopy.	2008-10-24	18778828
Long-lasting breaches in the bladder epithelium lead to storage dysfunction with increase in bladder PGE2 levels in the rat.	2008-08	18550866
Periodontal tissue regeneration using fibroblast growth factor-2: randomized controlled phase II clinical trial.	2008-07-02	18596969
Loxoprofen sodium treatment for elderly men with refractory nocturia: effect on night-time urine production.	2008-05	18452468
Analgesic effect of percutaneously absorbed non-steroidal anti-inflammatory drugs: an experimental study in a rat acute inflammation model.	2008-01-31	18234123
Short-term effect of COX-2 selective inhibitor as an adjunct for the treatment of periodontal disease: a clinical double-blind study in humans.	2008	19180322
Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats.	2008	18758904
[Case of loxoprofen sodium-induced eosinophilic pneumonia that occurred ipsilaterally after VATS lobectomy for lung cancer].	2007-10	18018630
Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report.	2007-10	17357801
NSAID loxoprofen inhibits high threshold or wide dynamic range neuronal responses in the rat at different time-courses.	2007-09-28	18443376
Education and Imaging. Gastrointestinal: ileal ulcers induced by non-steroidal anti-inflammatory drugs.	2007-08	17688672
Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis.	2007-07	17657553
Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide.	2007-03	17291297
Skin irritation in transdermal drug delivery systems: a strategy for its reduction.	2007-02	17191093
Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.	2007-01-01	17196469
Pharmacokinetics and bioequivalence study of two brands of loxoprofen tablets in healthy volunteers.	2007	17915642
Influence of loxoprofen use on recovery from naturally acquired upper respiratory tract infections: a randomized controlled trial.	2007	17675766
Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan.	2006-09	16821007
[Epidural infusion of low dose bupivacaine after combined spinal-epidural anesthesia using needle through needle method provided no analgesic effect on postoperative pain after caesarian section].	2006-08	16910476
Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery.	2006-07	16540287
[Cluster like headache in a patient with the Maffucci's syndrome].	2006-06	16856522
Direct and simultaneous analysis of loxoprofen and its diastereometric alcohol metabolites in human serum by on-line column switching liquid chromatography and its application to a pharmacokinetic study.	2006-05-01	16563885
Prostaglandin facilitates afferent nerve activity via EP1 receptors during urinary bladder inflammation in rats.	2006-04	16707842
[A case of takotsubo cardiomyopathy provoked by taking a new quinolone antibiotic drug and a non-steroidal anti-inflammatory drug].	2006-02	16634537
Pseudogout attack induced during etidronate disodium therapy.	2006	16633934

Patents

Sample Use Guides

In Vivo Use Guide

For the use in reducing inflammation and pain induced by rheumatoid arthritis, osteoarthritis, In general, for adults, take 1 tablet (60 mg of loxoprofen sodium) at a time, 3 times a day. If taken as on-demand use, take 1 to 2 tablets (60 to 120 mg) at a time. For the use in reducing fever or pain induced by acute inflammation of upper respiratory tract: In general, for adults, take 1 tablet (60 mg of loxoprofen sodium) at a time, as needed. Usually up to twice a day. Do not exceed 3 tablets (180 mg) a day.

Route of Administration: Oral

In Vitro Use Guide

Loxoprofen induced apoptosis more effectively in cultured human gastric cancer cells than in the primary culture. Loxoprofen exhibited much lower membrane permeabilizing activities than did indomethacin and celecoxib. Low direct cytotoxicity of loxoprofen observed in vitro is involved in its relative safety on production of gastric lesions in clinical situation.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:49:40 GMT 2025` Edited by `admin` on `Mon Mar 31 18:49:40 GMT 2025`
Record UNII	3583H0GZAP
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LOXOPROFEN ACID

Preferred Name

English

LOXOPROFEN

Official Name

English

loxoprofen [INN]

Common Name

English

Loxoprofen [WHO-DD]

Common Name

English

(±)-P-((2-OXOCYCLOPENTYL)METHYL)HYDRATROPIC ACID

Common Name

English

LOXOPROFEN [MI]

Common Name

English

2-(4-((2-OXOCYCLOPENTAN-1-YL)METHYL)PHENYL)PROPIONIC ACID

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1323